Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

110.04 +0.24 (+0.22%)
Official Closing Price Updated: 7:00 PM EST, Dec 2, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,943,603
Open 109.00
Bid (Size) 109.65 (5)
Ask (Size) 110.13 (1)
Prev. Close 109.80
Today's Range 108.71 - 110.09
52wk Range 71.50 - 110.98
Shares Outstanding 2,531,374,696
Dividend Yield 2.36%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Will Black Friday Push The S&P 500 Over Its 200DMA?
U.S. stocks reversed the rally spurred by inflation data. Fed officials dispelled hopes that the central bank would moderate interest rate increases. 
Via Talk Markets
What Bear Market? This Top-Performing Dow Stock Has Thrived in 2022.
The company is having a record-smashing year. 
Via The Motley Fool

Performance

YTD
+43.15%
+43.15%
1 Month
+10.93%
+10.93%
3 Month
+27.33%
+27.33%
6 Month
+22.48%
+22.48%
1 Year
+49.88%
+49.88%

More News

Read More
Should Investors Consider These 3 Low-Beta Stocks?
Via Talk Markets
Merck & Co Unusual Options Activity
Via Benzinga
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
From Merck & Co., Inc.
Via Business Wire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
Via Benzinga
Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck Announces First-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
3 Dow Stocks to Take Seriously in 2023
Via InvestorPlace
Cramer Expects Dow's Outperformance To Last 'Longer' As Traders Chase 'Old-Fashioned, Profitable' Companies Amid Uncertainty
Via Benzinga
3 Reasons Pfizer Stock Will Crush the Broader Market in 2023
Via The Motley Fool
Stocks Take A Hit As Wall Street Eyes China Covid Unrest
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck & Co Unusual Options Activity
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
3 Biotech Stocks Smart Investors Should Be Buying Up Now
Via InvestorPlace
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
7 Stocks on the Perfect 10 List
Via InvestorPlace
Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle
Via Investor's Business Daily
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Via Investor's Business Daily
Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month
Via Benzinga
10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.